Wuxi apptec completed the preclinical research of anti her2-adc

In the evening of April 24, it was announced that with the concerted efforts of Zhejiang Pharmaceutical, ambrx Inc and Wuxi Wuxi Wuxi pharmaceutical Kant Biotechnology Co., Ltd (hereinafter referred to as Wuxi pharmaceutical Kant), pharmaceutical Kant has recently successfully completed the preclinical research work of a new antibody coupled drug anti her2-adc, as well as the technological development and production of the original solution and preparation of the product At present, the preparation of the application materials for clinical research license of new drugs in Australia and China is under way Zhejiang Pharmaceutical said that up to now, the cooperation project has successfully completed the pre clinical research and development of anti her2-adc products, and the results are in line with expectations However, the research and development of new drugs is a long-term work There are many uncertain factors whether the next step can smoothly enter the clinical trials and eventually become new drugs Please pay attention to the investment risks In fact, on June 14, 2013, Zhejiang Pharmaceutical released a notice on signing the cooperative development and license agreement with ambrx Inc According to the cooperative development and license agreement signed by the company and ambrx Inc., the two parties will cooperate in the research and development and commercialization of new antibody coupling drug anti her2-adc products At the same time, the two parties agree to entrust Wuxi yaomingkant Biotechnology Co., Ltd (hereinafter referred to as yaomingkant) to be responsible for the preclinical research and production process development of anti her2-adc products According to the public information, ambrx Inc is an innovative biotechnology company, mainly engaged in research and development of biomedical technology The company has more than 700 patents in the world and 30 patent applications in China The core competitiveness of the company is in the field of protein drug research and development technology, such as protein site conjugation technology, non natural amino acid site insertion technology of protein sequence Ambrx Inc has established cooperative relationships with a number of international pharmaceutical giants, such as MSD and Merck (in 2012, they acquired a patent for a kind of MS treatment drug under research, and will obtain the equity of ambrx, with the name of arx424), Lilly, Bristol Myers Squibb, etc The simultaneous interpreting of the new HER2-ADC anti drug products is a monoclonal antibody Compared with the traditional ADC (antibody drug conjugates), monoclonal antibodies are highly specific, single ingredients and low toxicity HER2, the target of anti her2-adc products, has been fully studied The sales of Herceptin, a monoclonal antibody developed by Roche for this target, reached US $5.6 billion in 2011 Theoretically, new drugs have better therapeutic effect than traditional drugs, so it can be said that the market potential of this drug is very large.